242 related articles for article (PubMed ID: 37864601)
21. Remdesivir, Renal Function and Short-Term Clinical Outcomes in Elderly COVID-19 Pneumonia Patients: A Single-Centre Study.
Biancalana E; Chiriacò M; Sciarrone P; Mengozzi A; Mechelli S; Taddei S; Solini A
Clin Interv Aging; 2021; 16():1037-1046. PubMed ID: 34113086
[TBL] [Abstract][Full Text] [Related]
22. Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020.
Rocca E; Gauffin O; Savage R; Vidlin SH; Grundmark B
Drug Saf; 2021 Sep; 44(9):987-998. PubMed ID: 34374967
[TBL] [Abstract][Full Text] [Related]
23. Safety and effectiveness of remdesivir in hospitalized patients with COVID-19 and severe renal impairment: experience at a large medical center.
Chang HY; Hsu CC; Hu LF; Chou CY; Chang YL; Lu CC; Chang LJ
Ann Med; 2024 Dec; 56(1):2361843. PubMed ID: 38830017
[TBL] [Abstract][Full Text] [Related]
24. Remdesivir: A beacon of hope from Ebola virus disease to COVID-19.
Nili A; Farbod A; Neishabouri A; Mozafarihashjin M; Tavakolpour S; Mahmoudi H
Rev Med Virol; 2020 Nov; 30(6):1-13. PubMed ID: 33210457
[TBL] [Abstract][Full Text] [Related]
25. Use of remdesivir in children with COVID-19 infection: a quick narrative review.
La Tessa A; Motisi MA; Marseglia GL; Cardinale F; Licari A; Manti S; Tosca M; Del Giudice MM; De Filippo M; Galli L; Chiappini E
Acta Biomed; 2021 Nov; 92(S7):e2021524. PubMed ID: 34842595
[TBL] [Abstract][Full Text] [Related]
26. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Spinner CD; Gottlieb RL; Criner GJ; Arribas López JR; Cattelan AM; Soriano Viladomiu A; Ogbuagu O; Malhotra P; Mullane KM; Castagna A; Chai LYA; Roestenberg M; Tsang OTY; Bernasconi E; Le Turnier P; Chang SC; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wang H; Gaggar A; Brainard DM; McPhail MJ; Bhagani S; Ahn MY; Sanyal AJ; Huhn G; Marty FM;
JAMA; 2020 Sep; 324(11):1048-1057. PubMed ID: 32821939
[TBL] [Abstract][Full Text] [Related]
27. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.
Williamson BN; Feldmann F; Schwarz B; Meade-White K; Porter DP; Schulz J; van Doremalen N; Leighton I; Yinda CK; Pérez-Pérez L; Okumura A; Lovaglio J; Hanley PW; Saturday G; Bosio CM; Anzick S; Barbian K; Cihlar T; Martens C; Scott DP; Munster VJ; de Wit E
Nature; 2020 Sep; 585(7824):273-276. PubMed ID: 32516797
[TBL] [Abstract][Full Text] [Related]
28. Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study.
Joo EJ; Ko JH; Kim SE; Kang SJ; Baek JH; Heo EY; Shi HJ; Eom JS; Choe PG; Bae S; Ra SH; Kim DY; Kim BN; Kang YM; Kim JY; Chung JW; Chang HH; Bae S; Cheon S; Park Y; Choi H; Lee E; Lee BY; Park JW; Sohn Y; Heo JY; Kim SH; Peck KR
J Korean Med Sci; 2021 Mar; 36(11):e83. PubMed ID: 33754512
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcomes and safety of remdesivir in hospitalized individuals with COVID-19, with or without severe renal impairment.
Chang MC; Wu PF; Ho YC; Lin WY; Wu CY; Liu SY; Liu CJ; Lin YT
J Infect Public Health; 2024 Jul; 17(7):102460. PubMed ID: 38820894
[TBL] [Abstract][Full Text] [Related]
30. Remdesivir as a broad-spectrum antiviral drug against COVID-19.
Hong YN; Xu J; Sasa GBK; Zhou KX; Ding XF
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):541-548. PubMed ID: 33506946
[TBL] [Abstract][Full Text] [Related]
31. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
Ader F; Bouscambert-Duchamp M; Hites M; Peiffer-Smadja N; Poissy J; Belhadi D; Diallo A; Lê MP; Peytavin G; Staub T; Greil R; Guedj J; Paiva JA; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
Lancet Infect Dis; 2022 Feb; 22(2):209-221. PubMed ID: 34534511
[TBL] [Abstract][Full Text] [Related]
32. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.
Ye ZW; Yuan S; Chan JF; Zhang AJ; Yu CY; Ong CP; Yang D; Chan CC; Tang K; Cao J; Poon VK; Chan CC; Cai JP; Chu H; Yuen KY; Jin DY
Emerg Microbes Infect; 2021 Dec; 10(1):291-304. PubMed ID: 33538646
[TBL] [Abstract][Full Text] [Related]
33. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment.
Khazir J; Maqbool T; Mir BA
Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.
Negru PA; Radu AF; Vesa CM; Behl T; Abdel-Daim MM; Nechifor AC; Endres L; Stoicescu M; Pasca B; Tit DM; Bungau SG
Biomed Pharmacother; 2022 Mar; 147():112700. PubMed ID: 35131656
[TBL] [Abstract][Full Text] [Related]
35. Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review.
Yang CJ; Wei YJ; Chang HL; Chang PY; Tsai CC; Chen YH; Hsueh PR
J Microbiol Immunol Infect; 2021 Feb; 54(1):27-36. PubMed ID: 33060041
[TBL] [Abstract][Full Text] [Related]
36. A Valid Warning or Clinical Lore: an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort.
Ackley TW; McManus D; Topal JE; Cicali B; Shah S
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33229428
[TBL] [Abstract][Full Text] [Related]
37. Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence.
Lin HXJ; Cho S; Meyyur Aravamudan V; Sanda HY; Palraj R; Molton JS; Venkatachalam I
Infection; 2021 Jun; 49(3):401-410. PubMed ID: 33389708
[TBL] [Abstract][Full Text] [Related]
38. What is the role of remdesivir in patients with COVID-19?
Beigel JH
Curr Opin Crit Care; 2021 Oct; 27(5):487-492. PubMed ID: 34353998
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis.
Piscoya A; Ng-Sueng LF; Parra Del Riego A; Cerna-Viacava R; Pasupuleti V; Roman YM; Thota P; White CM; Hernandez AV
PLoS One; 2020; 15(12):e0243705. PubMed ID: 33301514
[TBL] [Abstract][Full Text] [Related]
40. Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score.
Sellers J; Chang J; Jones J; Hintze TD
Pulm Pharmacol Ther; 2023 Feb; 78():102188. PubMed ID: 36603741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]